|
|
Combination
temozolomide (T) and pegylated liposomal doxorubicin (C) in patients with
recurrent glioblastoma multiforme (GBM)
S. L. Chua, M. A. Rosenthal, D. Ashley, A.-M.
Woods, A. Dowling, L. Cher
Centre
Developmental Cancer Therapeutics; The Royal Melbourne Hospital, Melbourne,
Australia; Royal Children's Hospital, Melbourne, Australia; St Vincent's
Hospital, Melbourne, Australia; Austin and Repatriation Medical Centre,
Melbourne, Australia.
T has established activity in the treatment of
recurrent GBM.
Caelyx (C), a liposomal doxorubicin, has established activity in a broad range
of tumours but has not been extensively evaluated in the treatment of GBM.
Phase I data suggest that T and C can be combined safely at full dose.
Combination T (200 mg/m2 orally Day 1-5) and C (40 mg/m2 IV Day 1) was given q4
weekly in patients (pts) with recurrent GBM.
Currently, 22 pts have received a total of 103 cycles (median 3 cycles) with 3
patients receiving treatment.
The median age was 55 years (range 31-80 years) and 17 were male.
All pts had received radiotherapy, but only two had received prior chemotherapy.
1 patient (pt) had a complete response (5%), 3 pts had partial responses (14%),
and 11 pts had stable disease (50%).
The median time to progression for the cohort is 3.2+ months (range 1-13+
months).
Seven pts (32%) were progression-free at 6 months.
Hematological toxicity included: Grade 3/4 neutropenia in 4 pts (19%), Grade 3/4
thrombocytopenia in 4 pts (18%).
Grade 3 non-hematologic toxicity included: rash in 3pts (14%), nausea and
vomiting in 1pt (5%), hypersensitivity reaction to Caelyx in 3pts (14%) and
palmar-plantar toxicity in 1pt (5%).
In conclusion, the combination of T and C is well tolerated and has significant
activity in the treatment of recurrent GBM.
© Copyright 2003
American Society of Clinical Oncology All rights
reserved worldwide
Source:
http://www.asco.org/ac/1,1003,_12-002489-00_18-002003-00_19-00100604-00_29-00A,00.asp?cat=CNS+Tumors&parent=
Central+Nervous+System+Tumors&returnpid=2325&SubCat_ID=4 |